| [1] |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9.0000000000002108.
|
| [2] |
Sung H， Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
| [3] |
Hu C, Liu T, Han C, et al. HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF 2BP 2 to stabilize m 6A-MYC expression[J]. Int J Biol Sci, 2022, 18(2): 507-521. DOI: 10.7150/ijbs.67770.
|
| [4] |
Burmeister CA, Khan SF, Schäfer G, et al. Cervical cancer therapies: current challenges and future perspectives[J]. Tumour Virus Res, 2022, 13: 200238. DOI: 10.1016/j.tvr.2022.200238.
|
| [5] |
Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update[J]. Int J Gynaecol Obstet, 2021, 155 (Suppl 1): 28-44. DOI: 10.1002/ijgo.13865.
|
| [6] |
Bhatla N, Denny L. FIGO cancer report 2018[J]. Int J Gynecol Obstet, 2018, 143 (Suppl 2): 2-3. DOI: 10.1002/ijgo.12608.
|
| [7] |
|
| [8] |
Himiniuc LM, Toma BF, Popovici R, et al. Update on the use of nanocarriers and drug delivery systems and future directions in cervical cancer[J]. J Immunol Res, 2022, 2022: 1-11. DOI: 10.1155/2022/1636908.
|
| [9] |
Mutlu L, Tymon-Rosario J, Harold J, et al. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer[J]. Expert Rev Anticancer Ther, 2022, 22(6): 633-645. DOI: 10.1080/14737140.2022.2075348.
|
| [10] |
Gopu P, Antony F, Cyriac S, et al. Updates on systemic therapy for cervical cancer[J]. Indian J Med Res, 2021, 154(2): 293-302. DOI: 10.4103/ijmr.IJMR_4454_20.
|
| [11] |
Sharma S, Deep A, Sharma AK. Current treatment for cervical cancer: an update[J]. Anticancer Agents Med Chem, 2020, 20(15): 1768-1779. DOI: 10.2174/1871520620666200224093301.
|
| [12] |
Rahmani AH, ABabiker AY, Alsahli MA, et al. Prognostic significance of vascular endothelial growth factor (VEGF) and Her-2 protein in the genesis of cervical carcinoma[J]. Open Access Maced J Med Sci, 2018, 6(2): 263-268. DOI: 10.3889/oamjms.2018.089.
|
| [13] |
Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin ®) in cancer treatment: a review of 15 years of clinical experience and future outlook[J]. Cancer Treat Rev, 2020, 86: 102017. DOI: 10.1016/j.ctrv.2020.102017.
|
| [14] |
Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)[J]. Lancet, 2017, 390(10103): 1654-1663. DOI: 10.1016/S0140-6736(17)31607-0.
|
| [15] |
de Aguiar RB, de Moraes JZ. Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors[J]. Front Immunol, 2019, 10: 1023. DOI: 10.3389/fimmu.2019.01023.
|
| [16] |
Li S, Ma YM, Zheng PS, et al. GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2[J]. J Exp Clin Cancer Res, 2018, 37(1): 80. DOI: 10.1186/s13046-018-0744-0.
|
| [17] |
Liu Y, An Q, Zhao X. A pan-HER-targeted approach for recurrent or late-stage cervical cancer therapy: mechanisms, recent advances, and clinical prospects[J]. Eur Rev Med Pharmacol Sci, 2020, 24(8): 4123-4131. DOI: 10.26355/eurrev_202004_20992.
|
| [18] |
Benson R, Pathy S, Kumar L, et al. Locally advanced cervical cancer-neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: a phase Ⅱ study[J]. J Cancer Res Ther, 2019, 15(6): 1359-1364. DOI: 10.4103/jcrt.JCRT_39_18.
|
| [19] |
|
| [20] |
|
| [21] |
Liu X, Zhang X, Liu C, et al. Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer [J]. Discov Oncol, 2022, 13(1): 96. DOI: 10.1007/s12672-022-00560-8.
|
| [22] |
Han X, Chang WW, Xia X. Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer[J]. Front Oncol, 2022, 12: 996495. DOI: 10.3389/fonc.2022.996495.
|
| [23] |
|
| [24] |
D′Oria O, Corrado G, Laganà AS, et al. New advances in cervical cancer: from bench to bedside[J]. Int J Environ Res Public Heath, 2022, 19(12): 7094. DOI: 10.3390/ijerph19127094.
|
| [25] |
Stevanovi S, Helman SR, Wunderlich JR, et al. A phase Ⅱ study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers[J]. Clin Cancer Res, 2019, 25(5): 1486-1493. DOI: 10.1158/1078-0432.CCR-18-2722.
|
| [26] |
Huang H， Nie CP, Liu XF, et al. Phase Ⅰ study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer[J]. J Clin Invest, 2022, 132(15): e157726. DOI: 10.1172/JCI157726.
|
| [27] |
Son J, George GC, Nardo M, et al. Adoptive cell therapy in gynecologic cancers: a systematic review and Meta-analysis[J]. Gynecol Oncol, 2022, 165(3): 664-670. DOI: 10.1016/j.ygyno.2022.03.013.
|
| [28] |
Xu Q, Wang J, Sun Y, et al. Efficacy andsafety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phaseⅡtrial[J]. J Clin Oncol, 2022, 40(16): 1795-1805. DOI: 10.1200/JCO.21.02091.
|
| [29] |
Ota N, Yoshimoto Y， Darwis NDM, et al. High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy[J]. Jpn J Radiol, 2022, 40(5): 534-541. DOI: 10.1007/s11604-021-01230-5.
|
| [30] |
Liang Y, Yu M, Zhou C, et al. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy[J]. Diagn Pathol, 2020, 15(1): 67. DOI: 10.1186/s13000-020-00977-1.
|
| [31] |
Feng CH, Mell LK, Sharabi AB, et al. Immunotherapy with radiotherapy and chemoradiotherapy for cervical cancer[J]. Semin Radiat Oncol, 2020, 30(4): 273-280. DOI: 10.1016/j.semradonc.2020.05.003.
|
| [32] |
Wang R, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge[J]. Cancer Lett, 2020, 471: 88-102. DOI: 10.1016/j.canlet.2019.11.039.
|
| [33] |
Rahangdale L, Mungo C, O′Connor S, et al. Human papillomavirus vaccination and cervical cancer risk[J]. BMJ, 2022, 379: e070115. DOI: 10.1136/bmj-2022-070115.
|
| [34] |
Alhashimi M, Elkashif A, Sayedahmed EE, et al. Nonhuman adenoviral vector-based platforms and their utility in designing next generation of vaccines for infectious diseases[J]. Viruses, 2021, 13(8): 1493. DOI: 10.3390/v13081493.
|
| [35] |
Wang WC， Sayedahmed EE, Mittal SK. Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy[J]. Viruses, 2022, 14(12): 2727. DOI: 10.3390/v14122727.
|
| [36] |
Haghighi D, Yazdani S, Farzanehpour M, et al. Combined extract of heated TC1, a heat-killed preparation of Lactobacillus casei and alpha-galactosyl ceramide in a mouse model of cervical cancer[J]. Infect Agents Cancer, 2022, 17(1): 51. DOI: 10.1186/s13027-022-00464-w.
|
| [37] |
Xie L, Li Y. Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development[J]. Vaccine, 2022, 40(49): 7022-7031. DOI: 10.1016/j.vaccine.2022.10.047.
|
| [38] |
Hollenberg RK, Krieger DR, Samuels R, et al. Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population[J]. Hum Vaccin Immunother, 2020, 16(6): 1404-1412. DOI: 10.1080/21645515.2019.1695459.
|
| [39] |
Tang J, Li M, Zhao C, et al. Therapeutic DNA vaccines against HPV-related malignancies: promising leads from clinical trials[J]. Viruses, 2022, 14(2): 239. DOI: 10.3390/v14020239.
|
| [40] |
Zhang Y, Lin S, Wang XY, et al.Nanovaccines for cancer immunotherapy[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2019, 11(5): e1559. DOI: 10.1002/wnan.1559.
|
| [41] |
Peng S, Tan M, Li YD, et al. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model[J]. Cancer Immunol Immunother, 2021, 70(4): 1049-1062. DOI: 10.1007/s00262-020-02754-x.
|
| [42] |
Einstein MH, Roden RBS, Ferrall L, et al. Safety run-in of intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN protein vaccination as treatment for HPV16 ＋ ASC-US, ASC-H, or LSIL/CIN1[J]. Cancer Prev Res (Phila), 2023, 16(4): 219-227. DOI: 10.1158/1940-6207.CAPR-22-0413.
|
| [43] |
Tseng SH, Cheng MA, Farmer E, et al. Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8 ＋ T cell-mediated antitumor immunity[J]. J Immunother Cancer, 2022, 10(4): e004342. DOI: 10.1136/jitc-2021-004342.
|
| [44] |
Dhandapani H, Seetharaman A, Jayakumar H, et al. Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3 ＋ cells in vitro[J]. J Gynecol Oncol, 2021, 32(4): e59. DOI: 10.3802/jgo.2021.32.e59.
|
| [45] |
Hou YJ, Yang XX, Liu RQ, et al. Pathological mechanism of photodynamic therapy and photothermal therapy based on nanoparticles[J]. Int J Nanomedicine, 2020, 15: 6827-6838. DOI: 10.2147/IJN.S269321.
|
| [46] |
Unanyan A, Pivazyan L, Davydova J, et al. Efficacy of photodynamic therapy in women with HSIL, LSIL and early stage squamous cervical cancer: a systematic review and Meta-analysis[J]. Photodiagn Photodyn Ther, 2021, 36: 102530. DOI: 10.1016/j.pdpdt.2021.102530.
|
| [47] |
Zafari J, Zadehmodarres S, Javani Jouni F, et al. Investigation into the effect of photodynamic therapy and cisplatin on the cervical cancer cell line (A2780)[J]. J Lasers Med Sci, 2020, 11(Suppl 1): S85-S91. DOI: 10.34172/jlms.2020.S14.
|
| [48] |
Vendette ACF, Piva HL, Muehlmann LA, et al. Clinical treatment of intra-epithelia cervical neoplasia with photodynamic therapy[J]. Int J Hyperth, 2020, 37(3): 50-58. DOI: 10.1080/02656736.2020.1804077.
|
| [49] |
Niu J, Cheng M, Hong Z, et al. The effect of 5-aminolaevulinic acid Photodynamic therapy versus CO 2 laser in the treatment of cervical low-grade squamous intraepithelial lesions with high-risk HPV infection: a non-randomized, controlled pilot study[J]. Photodiagn Photodyn Ther, 2021, 36: 102548. DOI: 10.1016/j.pdpdt.2021.102548.
|
| [50] |
Wang L, Liu X, Zhang J, et al. Evaluation of the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy in women with high-risk HPV persistent infection after cervicalconization[J]. Photodiagn Photodyn Ther, 2022, 40: 103144. DOI: 10.1016/j.pdpdt.2022.103144.
|
| [51] |
Razlog R, Kruger CA, Abrahamse H. Enhancement of conventional and photodynamic therapy for treatment of cervical cancer with cannabidiol[J]. Integr Cancer Ther, 2022, 21: 15347354221092706. DOI: 10.1177/15347354221092706.
|
| [52] |
Hu Z. Therapeuti cantibody-like immunoconjugates against tissue factor with the potential to treat angiogenesis-dependent as well as macrophage-associated human diseases[J]. Antibodies, 2018, 7(1): 8. DOI: 10.3390/antib7010008.
|
| [53] |
Yin X, Lu Y, Zou M, et al. Synthesis and characterization of salinomycin-loaded high-density lipoprotein and its effects on cervical cancer cells and cervical cancer stem cells[J]. Int J Nanomed, 2021, 16: 6367-6382. DOI: 10.2147/IJN.S326089.
|
| [54] |
Zhu X, Long L, Xiao H, et al. Cancer-derived exosomal miR-651 as a diagnostic marker restrains cisplatin resistance and directly targets ATG3 for cervical cancer[J]. Dis Markers, 2021, 2021: 1544784. DOI: 10.1155/2021/1544784.
|
| [55] |
Gao C, Wu P, Yu L, et al. The application of CRISPR/Cas9 system in cervical carcinogenesis[J]. Cancer Gene Ther, 2022, 29(5): 466-474. DOI: 10.1038/s41417-021-00366-w.
|
| [56] |
Nile A, Nile SH, Shin J, et al. Quercetin-3-glucoside extracted from apple pomace induces cell cycle arrest and apoptosis by increasing intracellular ROS levels[J]. Int J Mol Sci, 2021, 22(19): 10749. DOI: 10.3390/ijms221910749.
|